LABORATOIRES EUROMEDIS (ALEMG.PA) Fundamental Analysis & Valuation

EPA:ALEMG • FR0000075343

Current stock price

4.7 EUR
-0.03 (-0.63%)
Last:

This ALEMG.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALEMG.PA Profitability Analysis

1.1 Basic Checks

  • ALEMG had negative earnings in the past year.
  • In multiple years ALEMG reported negative net income over the last 5 years.
  • In multiple years ALEMG reported negative operating cash flow during the last 5 years.
ALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -13.77%, ALEMG is doing worse than 72.58% of the companies in the same industry.
  • The Return On Equity of ALEMG (-33.03%) is worse than 70.97% of its industry peers.
Industry RankSector Rank
ROA -13.77%
ROE -33.03%
ROIC N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ALEMG.PA Yearly ROA, ROE, ROICALEMG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • ALEMG has a worse Gross Margin (26.77%) than 88.71% of its industry peers.
  • In the last couple of years the Gross Margin of ALEMG has remained more or less at the same level.
  • ALEMG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
ALEMG.PA Yearly Profit, Operating, Gross MarginsALEMG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALEMG.PA Health Analysis

2.1 Basic Checks

  • ALEMG has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALEMG has less shares outstanding
  • Compared to 1 year ago, ALEMG has an improved debt to assets ratio.
ALEMG.PA Yearly Shares OutstandingALEMG.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ALEMG.PA Yearly Total Debt VS Total AssetsALEMG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ALEMG has an Altman-Z score of 1.89. This is not the best score and indicates that ALEMG is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ALEMG (1.89) is worse than 61.29% of its industry peers.
  • A Debt/Equity ratio of 0.52 indicates that ALEMG is somewhat dependend on debt financing.
  • ALEMG has a Debt to Equity ratio (0.52) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z 1.89
ROIC/WACCN/A
WACCN/A
ALEMG.PA Yearly LT Debt VS Equity VS FCFALEMG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

  • A Current Ratio of 3.07 indicates that ALEMG has no problem at all paying its short term obligations.
  • ALEMG has a Current ratio of 3.07. This is amongst the best in the industry. ALEMG outperforms 82.26% of its industry peers.
  • A Quick Ratio of 2.25 indicates that ALEMG has no problem at all paying its short term obligations.
  • ALEMG's Quick ratio of 2.25 is amongst the best of the industry. ALEMG outperforms 83.87% of its industry peers.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.25
ALEMG.PA Yearly Current Assets VS Current LiabilitesALEMG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ALEMG.PA Growth Analysis

3.1 Past

  • ALEMG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -144.11%.
  • ALEMG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.59%.
  • The Revenue for ALEMG have been decreasing by -14.02% on average. This is quite bad
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%

3.2 Future

  • ALEMG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.07% yearly.
  • The Revenue is expected to decrease by -18.80% on average over the next years. This is quite bad
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALEMG.PA Yearly Revenue VS EstimatesALEMG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALEMG.PA Yearly EPS VS EstimatesALEMG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

3

4. ALEMG.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALEMG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALEMG is valuated reasonably with a Price/Forward Earnings ratio of 9.95.
  • Based on the Price/Forward Earnings ratio, ALEMG is valued cheaper than 90.32% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, ALEMG is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.95
ALEMG.PA Price Earnings VS Forward Price EarningsALEMG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEMG.PA Per share dataALEMG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • ALEMG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALEMG.PA Dividend Analysis

5.1 Amount

  • ALEMG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALEMG.PA Fundamentals: All Metrics, Ratios and Statistics

LABORATOIRES EUROMEDIS

EPA:ALEMG (3/23/2026, 7:00:00 PM)

4.7

-0.03 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-27
Earnings (Next)04-23
Inst Owners2.03%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.49M
Revenue(TTM)38.40M
Net Income(TTM)-5.48M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.95
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)0.47
Fwd EY10.05%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.38
BVpS5.78
TBVpS5.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.77%
ROE -33.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.77%
FCFM N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
F-ScoreN/A
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.07
Quick Ratio 2.25
Altman-Z 1.89
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

LABORATOIRES EUROMEDIS / ALEMG.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALEMG.PA.


Can you provide the valuation status for LABORATOIRES EUROMEDIS?

ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.


What is the profitability of ALEMG stock?

LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 1 / 10.


How financially healthy is LABORATOIRES EUROMEDIS?

The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.


How sustainable is the dividend of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

The dividend rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 0 / 10 and the dividend payout ratio is 0%.